Silexion Therapeutics Corp
SLXNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $70.3K in total; no superinvestor holds it.
Other share classesSLXN
13F holders, Q4 2025
Institutional positions in Silexion Therapeutics Corp as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- +1 vs. Q3 2025
- Shares held
- 2.37M
- −182.3K (−7.1%) vs. Q3 2025
- Total value
- $61.8K
- −$27.6K (−30.9%) vs. Q3 2025
- New holders
- 2
- 1 more added
- Sold out
- 1
- 1 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLXNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $70.3K |
| Q1 2026 | 19 | $47.7K |
| Q4 2025 | 22 | $61.8K |
| Q3 2025 | 22 | $89.8K |
| Q2 2025 | 22 | $107.6K |
| Q1 2025 | 25 | $199.1K |
| Q4 2024 | 26 | $91.7K |
| Q3 2024 | 32 | $106.1K |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Silexion Therapeutics Corp; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| HRT Financial LP | 21,260 | $0 | 0.00% | +21,260 | New |
| Bank of America Corp | 100 | $3 | 0.00% | 00.0% | Unchanged |
| Saba Capital Management, L.P. | 11,937 | $318 | 0.00% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 12,500 | $375 | 0.00% | +12,500 | New |
| Stifel Financial Corp | 16,000 | $416 | 0.00% | 00.0% | Unchanged |
| Gabelli Funds LLC | 30,496 | $793 | 0.00% | 00.0% | Unchanged |
| Neuberger Berman Group LLC | 31,552 | $820 | 0.00% | 00.0% | Unchanged |
| DuPont Capital Management Corp | 32,500 | $884 | 0.00% | 00.0% | Unchanged |
| Gabelli & Co Investment Advisers, Inc. | 38,150 | $992 | 0.00% | 00.0% | Unchanged |
| Mint Tower Capital Management B.V. | 25,000 | $1.00K | 0.00% | 00.0% | Unchanged |
| Tenor Capital Management Co., L.P. | 50,000 | $1.30K | 0.00% | 00.0% | Unchanged |
| Context Capital Management, LLC | 51,183 | $1.33K | 0.00% | 00.0% | Unchanged |
| Picton Mahoney Asset Management | 57,175 | $1.49K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 74,910 | $1.95K | 0.00% | 00.0% | Unchanged |
| Kepos Capital LP | 100,000 | $3.00K | 0.02% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 121,237 | $3.15K | 0.00% | +4,598+3.9% | Added |
| Security Benefit Life Insurance Co | 150,000 | $4.08K | 0.00% | 00.0% | Unchanged |
| Clear Street Group Inc. | 218,965 | $5.69K | 0.00% | −600−0.3% | Reduced |
| Aristeia Capital LLC | 236,546 | $6.29K | 0.00% | 00.0% | Unchanged |
| Linden Advisors LP | 337,500 | $8.57K | 0.00% | 00.0% | Unchanged |
| Polar Asset Management Partners Inc. | 743,475 | $19.3K | 0.00% | 00.0% | Unchanged |
| Oasis Management Co Ltd. | 11,111 | – | – | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −220,053−100.0% | Sold out |
| Cobblestone Capital Advisors LLC | – | – | – | – | Not filed |